Eccles-based testing firm BioClinics is aiming for a £2 million turnover in the next three years as it eyes expansion into Europe.
BioClinics is planning to roll out its DNA testing services to Spain and Scandinavia as well as opening an office in southern England.
The firm, which conducts workplace drug and alcohol testing along with weight-loss and DNA relationship testing, increased revenues by 20 per cent in its latest financial year to the end of August from £500,000 to £600,000.
Read: Daughter of murdered Daesh hostage Alan Henning wins promotion at Eccles firm
More: New headquarters for BioClinics
More: Eccles firm hits record £500,000 revenue
Now BioClinics is looking to accelerate growth after launching new services and appointing a director to spearhead its sales drive.
Simon Cady, 42, has joined the BioClinics board after being appointed sales and marketing director with a remit to grow the firm’s client base and revenues.
He has 15 years’ experience in the workplace drug and alcohol testing industry across the UK and internationally.
BioClinics has 14 staff at its headquarters and operates a network of 170 testing clinics and 80 mobile sample collection officers across the UK and Ireland.
Highlights of the year to August included the launch of lie detector testing in a joint venture with the British Polygraph Network.
The initiative has brought lie detector testing to Britain’s high streets for the first time.
Tests are available in more than 100 locations and are used by people who suspect their partners of infidelity, as well as by individuals concerned about family matters such as allegations of theft of valuables, drug-taking and domestic abuse.
In addition, companies are arranging tests in relation to alleged thefts from the workplace, to screen potential employees for links to drugs and alcohol, and to flush out candidates suspected of making false claims about their background and experience to secure a job.
Random and pre-employment workplace drug and alcohol testing overtook DNA relationship testing as BioClinics’ biggest income stream last year.
The firm has recently invested a five-figure sum in a dozen breathalyser devices as it ramps up testing in sectors such as rail, transport, utilities and maritime security.
BioClinics’ founder and scientific director Nichola McChrystal said: “We are entering into an extremely exciting period for the company.
“Simon’s arrival has strengthened our capabilities and the polygraph testing service has got off to a strong start.
“With several more new services in the pipeline and plans for expansion into Europe, we look to the future with confidence.”
Main image: Nichola McChrystal
